16 results about "Immunoglobulin A" patented technology

The inventions relates to Immunoglobulin A (IgA) or a pharmaceutical composition comprising IgA for use in the treatment of an infectious disease of or in an immune privileged organ, such as the eye, fetus, placenta, central nervous system (CNS) and / or testicles caused by a bacterial, fungal, viral or parasitic infection, in particular caused by bacteria of the human microbiome. IgA-coated pathogens can be addressed by FCAR+ and / or CD11c+ innate immune cells, for example by phagocytosis, or by activation of the complement system. The use of IgA or a pharmaceutical composition comprising IgA in immune privileged sites is advantageous because in contrast to IgG, IgA-coated pathogens do not trigger activation of C1q, a protein used for the controlled pruning of synapses. This prevents neuronal damage in said immune privileged organ(s), while at the same time allowing an antibody-mediated immune response in said organs.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

An immunological assay method for measuring a target substance in a sample, wherein at least one antigen-antibody reaction is performed in the presence of an enzyme that specifically decomposes immunoglobulin A (IgA).

The present disclosure refers to Immunoglobulin A (IgA) for use in a method for treating or preventing dry eyes in a patient wherein said Immunoglobulin A (IgA) is obtained from plasma, blood plasma or plasma fractions, and wherein said Immunoglobulin A (IgA) is administered to said patient in an effective dosage. In particular, the disclosure pertains to the use in a treatment or prevention of dry eye disease and the respective complications like infections. Further, the disclosure refers to IgA obtained from plasma, blood plasma or plasma fractions and a pharmaceutical composition comprising such IgA.

A molecular marker associated with immune parameters in yaks and use thereof in breeding are provided. A single nucleotide polymorphism (SNP) molecular marker associated with immune traits in yaks is identified through screening. The SNP molecular marker is located at position 26593056 on chromosome 3 of the yak reference genome version LU_Bosgru_v3.0, and a nucleotide at the position is G or A. The SNP molecular marker is utilized to quantify levels of immunoglobulin A, immunoglobulin G, and immunoglobulin M in a yak individual, providing a novel SNP molecular marker resource for non-diagnostic, marker-assisted selection of immune traits in yaks, thereby providing a basis for breeding yaks with enhanced immune competence.

A composition of matter including a deglycosylated IgA-binding moiety, a cellular receptor-binding moiety that binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting deglycosylated IgA-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing galactose-deficient IgA1 in a patient or subject.

Provided is a method of removal a pathogenic species from a system of a patient having Immunoglobulin A ("IgA") nephropathy by administering to the patient a degrader of galactose-deficient Immunoglobulin A ("Gd-IgA"), wherein the pathogenic species is a monomeric Gd-IgA, a dimeric Gd-IgA complex, a trimeric Gd-IgA complex, a tetrameric Gd-IgA complex, or a combination thereof.

The invention provides a method for removing IgA (Immunoglobulin A) and IgM (Immunoglobulin M) in human immunoglobulin for intravenous injection. The method comprises the following steps: S1) dissolving plasma component II + III precipitates to obtain a dissolved solution; s2) precipitating and centrifuging the dissolved solution by adopting n-caprylic acid or sodium caprylate to obtain supernate; s3) performing anion exchange column chromatography on the supernate to obtain first flow-through liquid and first washing liquid; s4) mixing the first flow-through liquid with the first washing liquid to obtain a column chromatography collection liquid; s5) performing strong anion membrane chromatography on the column chromatography collection liquid to obtain second flow-through liquid and second washing liquid; s6) mixing the second flow-through liquid and the second washing liquid to obtain a membrane chromatography collection liquid, and S7) sequentially performing first concentration, dialysis, first sterilization, incubation, ultrafiltration and second sterilization on the membrane chromatography collection liquid to obtain the human immunoglobulin for intravenous injection without IgA and IgM. According to the method disclosed by the invention, the IgA and IgM removal efficiency is remarkably improved through a multi-stage purification process.

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.

The invention provides an oral plant-probiotic heterologous multifunctional fusion exosome for targeted regulation and control of intestinal mucosa pIgR-IgA transport axis as well as a preparation method and application of the oral plant-probiotic heterologous multifunctional fusion exosome. The fusion exosome is constructed from a plant-derived exosome (such as a garlic exosome) and a probiotic-derived exosome (such as a bacteroides polymorpha exosome) through an ultrasonic membrane fusion technology. According to the invention, the fusion exosome is orally taken for the first time to specifically enhance the transfer of immune globulin A (IgA) mediated by a polyimmunoglobulin receptor (pIgR), so that the concentration of secreted IgA (SIgA) in an enteric cavity is improved, and the immune homeostasis of intestinal mucosa is fundamentally remodeled. In-vitro and in-vivo experiments prove that the core product GB-EV (garlic-bacteroides polymorpha fusion exosome) disclosed by the invention has excellent oral stability and colon targeting property, and can synergistically exert multiple effects of resisting oxidation, resisting inflammation, repairing intestinal barriers and reconstructing flora ecological balance; in an inflammatory bowel disease (IBD) prevention and treatment model, the exosome shows an excellent effect which is obviously superior to that of a single-source exosome and a control fusion exosome. The invention provides a brand new strategy for non-invasive targeted therapy of IBD.

Provided herein are glycoengineered polypeptides comprising: a first portion comprising one or more peptides that specifically bind to a target antibody (e.g., IgA1 or an immune complex comprising same, gd-IgA1 or an immune complex comprising same, or an anti-gd-IgA1 autoantibody or an immune complex comprising same); and a second portion comprising one or more glycans conjugated to the first portion at one or more glycosylation sites. Also provided herein are nucleic acid sequences encoding the provided glycoengineered polypeptides. Further provided herein are compositions comprising the glycoengineered polypeptides and / or nucleic acids encoding same, as well as methods of making and using them.

The invention belongs to the technical field of biomedicine, and discloses an automatic sketching and functional classification model of three-level lymphatic structure related ecological niche based on a space transcriptome and application. Aiming at the problem that traditional TLS typing depends on maturity and neglects spatial localization and function association, by integrating spatial transcriptome and pathological region analysis, TLS is divided into three functional subtypes: microbial response type TLS-G1, localization in a mucous membrane region, high expression of immunoglobulin A genes and mucous membrane defense genes; the inflammation-related bystander TLS-G2 is distributed in a para-tumor tissue and is used for enriching memory T cells and mast cells; and the anti-tumor reaction type TLS-G3 is positioned in a tumor core region and is used for highly expressing cytotoxic genes and immune checkpoint molecules. The method comprises the following steps: defining a TLS-flare feature gene set; the score of the gene set can predict immune checkpoint inhibitor treatment response, and is used for developing an immunotherapy prediction kit or optimizing a targeted therapy strategy.

The present invention belongs to the technical field of molecular biological detection, and particularly relates to a molecular marker associated with a yak immune index and the use thereof in breeding. In the present invention, an SNP molecular marker associated with a yak immune trait is obtained by means of screening. The marker is located at base position 26593056 on chromosome 3 of the yak reference genome assembly LU_Bosgru_v3.0, with the mutant base being G or A. In the present invention, the contents of immunoglobulin A, immunoglobulin G and immunoglobulin M in a yak individual can be obtained by using the SNP molecular marker, which provides a new SNP molecular marker resource for marker-assisted selection of yak immune traits for non-diagnostic purposes, thereby providing a basis for the breeding of yaks with high immunity.

The present application relates to the technical field of molecular biology detection, and provides a SNP molecular marker affecting yak immunoglobulin and application of the SNP molecular marker. The present application obtains, through screening, that the SNP molecular marker related to the yak immunity trait is located at the 43165308th base on the 21st chromosome of the yak reference genome LU_Bosgru_v3.0, and the mutation base is C or T. The molecular marker can determine the contents of immunoglobulin A and immunoglobulin M of a yak individual. The present application provides a new SNP molecular marker resource for marker-assisted selection of non-diagnostic yak immunity traits, and provides a basis for improving the breeding of yak immunity.

The application belongs to the technical field of biological feed, and discloses a composition for improving immunity of young pets and application thereof, wherein the composition comprises soybean peptides and beta-glucan, and the mass ratio of the soybean peptides to the beta-glucan is 5:1-10:1. Experiments show that the composition can significantly improve the weight growth rate of young pets, improve the body condition and fecal state, increase the content of serum protein, immunoglobulin and various immune factors, increase the level of fecal secreted immunoglobulin A, and effectively enhance the whole body immunity and intestinal mucosal immunity of young pets. The composition is safe and efficient, low in cost, and has strong compatibility with pet daily food, and is suitable for preparing pet food, animal feed and related additives, and can be widely used for immune enhancement and health care of various young pets such as cats and dogs, and solves the technical problems of single function, poor effect and high cost of existing products.

Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to a target antibody (e.g., an IgA1 or an immune complex comprising the same, a gd-IgA1 or an immune complex comprising the same, or an anti-gd-IgA1 autoantibody or an immune complex comprising the same) and a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites. Also provided herein are nucleic acid sequence encoding provided glycoengineered polypeptides. Further provided herein are compositions comprising glycoengineered polypeptides and / or nucleic acids encoding the same, as well as methods of making and using the same.